156 related articles for article (PubMed ID: 38606542)
21. Genomic Alterations in Langerhans Cell Histiocytosis.
Rollins BJ
Hematol Oncol Clin North Am; 2015 Oct; 29(5):839-51. PubMed ID: 26461146
[TBL] [Abstract][Full Text] [Related]
22. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
McClain K
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
[TBL] [Abstract][Full Text] [Related]
23. Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.
Gao XM; Li J; Cao XX
Cell Commun Signal; 2022 Dec; 20(1):195. PubMed ID: 36536400
[TBL] [Abstract][Full Text] [Related]
24. Pediatric Langerhans cell histiocytosis: state of the science and future directions.
Thacker NH; Abla O
Clin Adv Hematol Oncol; 2019 Feb; 17(2):122-131. PubMed ID: 30845115
[TBL] [Abstract][Full Text] [Related]
25. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
[TBL] [Abstract][Full Text] [Related]
26. Success of Trametinib in the Treatment of Langerhans Cell Histiocytosis With Novel MAPK Pathway Mutations.
Orr K; Hustak S; Beaudoin R; Ray A
J Pediatr Hematol Oncol; 2023 May; 45(4):e534-e538. PubMed ID: 36730444
[TBL] [Abstract][Full Text] [Related]
27. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.
Aricò M
Br J Haematol; 2016 Jun; 173(5):663-70. PubMed ID: 26913480
[TBL] [Abstract][Full Text] [Related]
28. Langerhans cell histiocytosis. Advances in pathogenesis and clinical practice.
Astigarraga I; García-Obregón S; Pérez-Martínez A; Gutiérrez-Carrasco I; Santa-María V; Iturrate CR; Reggiori ML; Carrillo TM; Torrent M;
An Pediatr (Engl Ed); 2022 Aug; 97(2):130.e1-130.e7. PubMed ID: 35869015
[TBL] [Abstract][Full Text] [Related]
29. [Status of Langerhans cell histiocytosis in children and adults].
Kudo K
Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
[TBL] [Abstract][Full Text] [Related]
30. BRAF gene mutations in synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland: a case report and literature review.
A Al Hamad M; Albisher HM; Al Saeed WR; Almumtin AT; Allabbad FM; A Shawarby M
BMC Cancer; 2019 Feb; 19(1):170. PubMed ID: 30795755
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
Geerlinks AV; Abla O
Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
[TBL] [Abstract][Full Text] [Related]
32. Remission of Congenital Multi-system Type Langerhans Cell Histiocytosis with Chemotherapy.
Tamefusa K; Ishida H; Washio K; Ishida T; Morita H; Shimada A
Acta Med Okayama; 2019 Feb; 73(1):61-65. PubMed ID: 30820055
[TBL] [Abstract][Full Text] [Related]
33. Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.
Tóth B; Kiss N; Hársing J; Kárpáti S; Csomor J; Bödör C; Tímár J; Rásó E
Virchows Arch; 2020 Nov; 477(5):749-753. PubMed ID: 32372223
[TBL] [Abstract][Full Text] [Related]
34. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside.
Apollonsky N; Lipton JM
J Pediatr Hematol Oncol; 2009 Jan; 31(1):53-6. PubMed ID: 19125089
[TBL] [Abstract][Full Text] [Related]
35. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH.
Sengal A; Velazquez J; Hahne M; Burke TM; Abhyankar H; Reyes R; Olea W; Scull B; Eckstein OS; Bigenwald C; Bollard CM; Yu W; Merad M; McClain KL; Allen CE; Chakraborty R
Blood; 2021 Apr; 137(13):1777-1791. PubMed ID: 33075814
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of multiple relapsed-refractory Langerhans cell histiocytosis with cyclosporine.
Özyörük D; Yozgat AK; Kaçar D; Yazal Erdem A; Işık M; Güzelküçük Z; Hacısalihoğlu Ş
Tumori; 2021 Dec; 107(6):NP120-NP122. PubMed ID: 34423687
[TBL] [Abstract][Full Text] [Related]
37. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
[TBL] [Abstract][Full Text] [Related]
38. Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
Messinger YH; Bostrom BC; Olson DR; Gossai NP; Miller LH; Richards MK
Pediatr Blood Cancer; 2020 Dec; 67(12):e28712. PubMed ID: 32991018
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis.
Mohapatra D; Gupta AK; Haldar P; Meena JP; Tanwar P; Seth R
Pediatr Hematol Oncol; 2023 Feb; 40(1):86-97. PubMed ID: 35616365
[TBL] [Abstract][Full Text] [Related]
40. Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications.
Zinn DJ; Chakraborty R; Allen CE
Oncology (Williston Park); 2016 Feb; 30(2):122-32, 139. PubMed ID: 26888790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
